CDKN1C Antikörper

Produktnummer ABIN967507

Produktdetails anti-CDKN1C Antikörper

Target: CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CDKN1C Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Marke: BD Pharmingen™

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: p57[Kip2] Recombinant Human

Klon: A120-1

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Applications for clone A120-1 include western blot analysis (1-2 µg/ml). SJCRH30 human rhabdomyosarcoma cells are suggested as a positive control (ATCC CRL-2061).

Kommentare:

Related Products: ABIN967389

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C.

Referenzen für anti-CDKN1C Antikörper (ABIN967507)

Graña, Reddy: "Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)." in: Oncogene, Vol. 11, Issue 2, pp. 211-9, (1995) (PubMed).

Lee, Reynisdóttir, Massagué: "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution." in: Genes & development, Vol. 9, Issue 6, pp. 639-49, (1995) (PubMed).

Matsuoka, Edwards, Bai, Parker, Zhang, Baldini, Harper, Elledge: "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene." in: Genes & development, Vol. 9, Issue 6, pp. 650-62, (1995) (PubMed).

Details zu CDKN1C

Target: CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C (p57, Kip2) (CDKN1C))

Andere Bezeichnung: p57 Kip2 (CDKN1C Produkte)

Hintergrund: Cyclin dependent kinase inhibitors (CdkIs) inhibit progression through the cell cycle by binding to cyclins, Cdks, or cyclin-Cdk complexes. CdkIs are classified into two groups based on protein structure. p57[Kip2] belongs to a group that also includes p27[Kip1] and p21 (also known as Sdi1, Cip1, Waf1 and Pic1). Members of this group have a homologous amino-terminal Cdk inhibitory domain. Members of the second group [p16 (INK4A), p15 (INK4B), p18 (INK4C), and p19 (INK4D)] contain ankyrin repeat motifs. p57[Kip2] is a potent, tight-binding inhibitor of several G1 and S phase cyclin-Cdk complexes including cyclin E-Cdk2, cyclin D2-Cdk4, and cyclin A-Cdk2. It inhibits the mitotic cyclin B1-Cdk1 complex to a lesser extent. mRNA studies suggest that p57[Kip2] expression is tissue-specific, the highest levels have been found in embryonic and adult skeletal muscle, heart, kidney, lung, eye and brain. This is in contrast to the widespread tissue expression of p27[Kip1] and p21 mRNA. The expression of p57[Kip2] to primarily terminally differentiated cells suggests that p57[Kip2] may play a specialized role in cell cycle control. Clone A120-1 reacts with human p57[Kip2]. Recombinant human p57[Kip2] was used as immunogen.

Molekulargewicht: 57 kDa

Pathways: Zellzyklus, Dopaminergic Neurogenesis